Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Cancer-Related Gene Mutations Drive Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia

Xiaoshuai Zhang, Zongru Li, Ya-Zhen Qin, Robert Peter Gale, Yueyun Lai, Hongxia Shi, Xiao Jun Huang, Qian Jiang

Blood (2022) 140 (Supplement 1): 9611–9613.

https://doi.org/10.1182/blood-2022-169397

Published: 2022

Journal Articles

The Application of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Aclarubicin in AML-MRC: A Single Center Case Control Study

Hao Jiang, Jing Liu, Xiaohong Liu, Jinsong Jia, Lizhong Gong, Shengye Lu, Xiaojun Huang, Jing Wang, Xiaosu Zhao, Yueyun Lai, Hongxia Shi, Yingjun Chang, Guorui Ruan

Blood (2021) 138 (Supplement 1): 2320.

https://doi.org/10.1182/blood-2021-149493

Published: 2021

Journal Articles

Mutations Based on Next-Generation Sequencing May be Complementally to Prognostic Risk in Myelodysplastic Syndromes

Jing Wang, MD, Jinsong Jia, Xiaohong Liu, Lizhong Gong, Shengye Lu, Yu Wang, Lanping Xu, Xiaohui Zhang, Chenhua Yan, Yueyun Lai, Xiaosu Zhao, PhD, Yazhen Qin, Guorui Ruan, Yingjun Chang, Hongxia Shi, Kaiyan Liu, Xiaojun Huang, Hao Jiang, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-140977

Published: 2020

Journal Articles

Comparable Efficacy and Safety of Chinese Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Study

Xuelin Dou, Yazhen Qin, Yueyun Lai, Hongxia Shi, Xiaojun Huang, MD, Qian Jiang, MD

Blood (2019) 134 (Supplement_1): 2940.

https://doi.org/10.1182/blood-2019-130081

Published: 2019

Journal Articles

Philadelphia-Positive Leukemia Patients With The Y253H Or F359V Mutations Have a High Risk Of Developing New Mutations In The Setting Of Dasatinib Resistance

Qian Jiang, Yazhen Qin, Yueyun Lai, Hao Jiang, Jing Wang, Hongxia Shi, MD, Xiaojun Huang, M.D Ph.D

Blood (2013) 122 (21): 5188.

https://doi.org/10.1182/blood.V122.21.5188.5188

Published: 2013

Journal Articles

Efficacy Analysis With Imatinib Monotherapy Was Superior To Allogeneic Hematopoietic Stem Transplantation In Pediatric Patients With Chronic Phase Of Chronic Myelogenous Leukemia

Hao Jiang, Daihong Liu, Lanping Xu, Kaiyan Liu, Shanshan Chen, MD, Bin Jiang, MD, Qian Jiang, Huan Chen, Yuhong Chen, Wei Han, MD, Xiaohui Zhang, Yazhen Qin, Yueyun Lai, Yanrong Liu, MD, PhD, Xiaojun Huang

Blood (2013) 122 (21): 4035.

https://doi.org/10.1182/blood.V122.21.4035.4035

Published: 2013

Journal Articles

Comparison of Response Over 6 Years Between Patients with Chronic Myeloid Leukemia Who Received Imatinib as Initial Therapy and Those Who Received Imatinib as Secondary Therapy.

Hao Jiang, MD, Xiaojun Huang, MD, PhD, Shanshan Chen, MD, Bin Jiang, Qian Jiang, PhD, Yazhen Qin, Yueyun Lai

Blood (2009) 114 (22): 4281.

https://doi.org/10.1182/blood.V114.22.4281.4281

Published: 2009

NARROW

Cancer-Related Gene Mutations Drive Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia

The Application of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Aclarubicin in AML-MRC: A Single Center Case Control Study

Mutations Based on Next-Generation Sequencing May be Complementally to Prognostic Risk in Myelodysplastic Syndromes

Comparable Efficacy and Safety of Chinese Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Study

Philadelphia-Positive Leukemia Patients With The Y253H Or F359V Mutations Have a High Risk Of Developing New Mutations In The Setting Of Dasatinib Resistance

Efficacy Analysis With Imatinib Monotherapy Was Superior To Allogeneic Hematopoietic Stem Transplantation In Pediatric Patients With Chronic Phase Of Chronic Myelogenous Leukemia

Comparison of Response Over 6 Years Between Patients with Chronic Myeloid Leukemia Who Received Imatinib as Initial Therapy and Those Who Received Imatinib as Secondary Therapy.

Email alerts

ASH Publications

American Society of Hematology

Cancer-Related Gene Mutations Drive Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia

The Application of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Aclarubicin in AML-MRC: A Single Center Case Control Study

Mutations Based on Next-Generation Sequencing May be Complementally to Prognostic Risk in Myelodysplastic Syndromes

Comparable Efficacy and Safety of Chinese Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Study

Philadelphia-Positive Leukemia Patients With The Y253H Or F359V Mutations Have a High Risk Of Developing New Mutations In The Setting Of Dasatinib Resistance

Efficacy Analysis With Imatinib Monotherapy Was Superior To Allogeneic Hematopoietic Stem Transplantation In Pediatric Patients With Chronic Phase Of Chronic Myelogenous Leukemia

Comparison of Response Over 6 Years Between Patients with Chronic Myeloid Leukemia Who Received Imatinib as Initial Therapy and Those Who Received Imatinib as Secondary Therapy.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only